Dual antiplatelet therapy (DAPT) segment accounted for around 27.5% in 2022 and will record 5.4% CAGR from 2023 to 2032 as individuals with Takotsubo Syndrome might also present concomitant cardiovascular conditions like coronary artery disease (CAD) or a past occurrence of acute coronary syndrome (ACS). Read More